More than 16,000 patients have filed a Yaz lawsuit so far for injuries based on the failure of Bayer to warn of the risks.
Yaz and Yasmin became widely used after heavy marketing by Bayer showing them as birth control alternatives that promised safety with limited PMS, bloating, and acne, compared to traditional oral contraceptives. An estimated 100 million women have been prescribed the drugs.
Today, Yaz is still among the most widely used birth control drugs in the United States. In recent years, however, the FDA, Institute for Safe Medication Practices, British Medical Journal, New England Journal of Medicine and other experts have warned that Yaz and Yasmin may be linked to blood clots.
Based on Bayer’s most recent financial records update, they have already spent around $2 billion to settle nearly 9,000 claims. More funds have been reserved for those affected, however, victims must still file a Yaz lawsuit to take part in the settlement, and time is limited.
Due to the number of patients filing a Yaz lawsuit, the cases were consolidated to a special federal Multi-District Litigation court in Illinois. This differs from a class action lawsuit in that claims are still handled individually, which can result in higher awards. Also, victims are free to choose their own legal counsel.
Bayer chose to settle the growing claims after a wave of repeated publications linking Yaz and Yasmin to blood clots.
In 2011, the British Medical Journal and FDA both warned that combined hormone drugs which contain drospirenone, such as Yaz and Yasmin, may substantially increase the risk of blood clots.
The Institute for Safe Medicine Practices reported in May of 2012 that Yaz and Yasmin ranked second highest in 2011 for the number of complications reported to the FDA. So far, the agency has received over 16,000 adverse reports related to Yaz or Yasmin just for DVT or pulmonary embolism.
Blood clots can cause serious or life-threatening conditions like stroke, deep vein thrombosis (DVT), or pulmonary embolism.